LONDON, June 10 (Reuters) -
Britain's drug regulatory agency said on Tuesday the U.S. Food and
Drug Administration was evaluating data on GlaxoSmithKline Plc's
<GSK.L> antidepressant Seroxat after the UK warned it should
not be given to children.
Medicines and Healthcare products Regulatory
Authority (MHRA) officials, addressing a news conference, said
Europe's CPMP expert committee on medicines had also been
alerted.
The MHRA recommended
Seroxat should not be used to treat depression in people under 18
after new data showed an increase in the rate of self-harm and
suicidal tendencies in those taking the drug in this age group.
Market data provided by
Reuters. Disclaimer Stock
quotes are delayed at least 15 minutes for Nasdaq, at least 20 minutes for
NYSE/AMEX. U.S. indexes are delayed at least 15 minutes with the
exception of S&P 500 which is real-time. Forbes 40
Index powered by Telemet.
News may
include latest headlines from Reuters.
.gif){kind=spacer}
.gif)
.gif){kind=spacer}